BG102716A - Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline - Google Patents

Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline

Info

Publication number
BG102716A
BG102716A BG102716A BG10271698A BG102716A BG 102716 A BG102716 A BG 102716A BG 102716 A BG102716 A BG 102716A BG 10271698 A BG10271698 A BG 10271698A BG 102716 A BG102716 A BG 102716A
Authority
BG
Bulgaria
Prior art keywords
treatment
endotheline
formulations
opposing
cardiac insufficiency
Prior art date
Application number
BG102716A
Other languages
Bulgarian (bg)
English (en)
Inventor
Joseph Lynch
You-Tang Shen
Original Assignee
Joseph Lynch
You-Tang Shen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joseph Lynch, You-Tang Shen filed Critical Joseph Lynch
Publication of BG102716A publication Critical patent/BG102716A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Photosensitive Polymer And Photoresist Processing (AREA)
BG102716A 1996-04-04 1998-08-21 Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline BG102716A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1488296P 1996-04-04 1996-04-04
PCT/US1997/003737 WO1997037665A1 (en) 1996-04-04 1997-03-19 Method of treating heart failure with endothelin antagonists

Publications (1)

Publication Number Publication Date
BG102716A true BG102716A (en) 1999-09-30

Family

ID=21768326

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102716A BG102716A (en) 1996-04-04 1998-08-21 Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline

Country Status (25)

Country Link
US (3) US5834483A (de)
EP (1) EP0906108B1 (de)
JP (2) JP3345891B2 (de)
KR (1) KR20000005178A (de)
CN (1) CN1215335A (de)
AT (1) ATE297739T1 (de)
AU (1) AU723351B2 (de)
BG (1) BG102716A (de)
BR (1) BR9708525A (de)
CA (1) CA2249330C (de)
CZ (1) CZ296098A3 (de)
DE (1) DE69733557T2 (de)
EA (1) EA003587B1 (de)
EE (1) EE9800315A (de)
ES (1) ES2241047T3 (de)
HU (1) HUP9903893A3 (de)
IL (1) IL126175A (de)
IS (1) IS4847A (de)
NO (1) NO984564L (de)
NZ (1) NZ331789A (de)
PL (1) PL329077A1 (de)
SK (1) SK130098A3 (de)
TR (1) TR199801988T2 (de)
UA (1) UA50761C2 (de)
WO (1) WO1997037665A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037665A1 (en) 1996-04-04 1997-10-16 Banyu Pharmaceutical Co., Ltd. Method of treating heart failure with endothelin antagonists
AU711936B2 (en) * 1996-08-09 1999-10-28 Banyu Pharmaceutical Co., Ltd. Stereoselective deoxygenation reaction
EP1049691B1 (de) 1998-01-21 2004-02-18 Banyu Pharmaceutical Co., Ltd. Substituierte 5-(2,2difluor-1,3-benzodioxol-5-yl) cyclopentenopyridinderivate
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
JPWO2004060885A1 (ja) * 2002-12-27 2006-05-11 株式会社カネカ 光学活性2−チオメチル−3−フェニルプロピオン酸誘導体およびその合成中間体の製造法
CA2545641A1 (en) 2003-11-17 2005-06-02 Novartis Ag Use of organic compounds
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
JP2007529459A (ja) 2004-03-17 2007-10-25 ノバルティス アクチエンゲゼルシャフト 治療に置けるレニン阻害剤の使用
JP4967136B2 (ja) 2005-06-24 2012-07-04 国立大学法人 東京医科歯科大学 薬剤溶出性ステント
WO2011116115A1 (en) 2010-03-16 2011-09-22 Novartis Ag Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
GB9007762D0 (en) * 1990-04-05 1990-06-06 Beecham Group Plc Novel compounds
US5565485A (en) * 1993-03-19 1996-10-15 Merck & Co., Inc. Biphenyl compounds useful or endothelin antagonists
ES2172535T3 (es) 1993-04-27 2002-10-01 Smithkline Beecham Corp Antagonistas de los receptores de la endotelina.
US5571813A (en) * 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
US5389620A (en) * 1993-08-18 1995-02-14 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
AU675870B2 (en) * 1993-08-18 1997-02-20 Msd K.K. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5658943A (en) * 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists
WO1997037665A1 (en) * 1996-04-04 1997-10-16 Banyu Pharmaceutical Co., Ltd. Method of treating heart failure with endothelin antagonists

Also Published As

Publication number Publication date
HUP9903893A2 (hu) 2001-04-28
EP0906108A4 (de) 2000-12-06
JP2002220337A (ja) 2002-08-09
ATE297739T1 (de) 2005-07-15
DE69733557D1 (de) 2005-07-21
AU723351B2 (en) 2000-08-24
JP2000510824A (ja) 2000-08-22
US6380195B1 (en) 2002-04-30
EE9800315A (et) 1999-06-15
ES2241047T3 (es) 2005-10-16
US6087360A (en) 2000-07-11
AU2202597A (en) 1997-10-29
EP0906108B1 (de) 2005-06-15
CA2249330C (en) 2005-08-09
DE69733557T2 (de) 2005-11-03
CA2249330A1 (en) 1997-10-16
CN1215335A (zh) 1999-04-28
PL329077A1 (en) 1999-03-15
HUP9903893A3 (en) 2001-05-28
IL126175A (en) 2003-05-29
EA199800889A1 (ru) 1999-04-29
WO1997037665A1 (en) 1997-10-16
UA50761C2 (uk) 2002-11-15
NO984564L (no) 1998-12-04
NZ331789A (en) 2000-05-26
NO984564D0 (no) 1998-09-30
IL126175A0 (en) 1999-05-09
BR9708525A (pt) 1999-08-03
CZ296098A3 (cs) 1999-06-16
EA003587B1 (ru) 2003-06-26
US5834483A (en) 1998-11-10
IS4847A (is) 1998-09-15
TR199801988T2 (xx) 2000-08-21
SK130098A3 (en) 1999-05-07
EP0906108A1 (de) 1999-04-07
JP3345891B2 (ja) 2002-11-18
KR20000005178A (ko) 2000-01-25

Similar Documents

Publication Publication Date Title
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
MY117032A (en) A novel compound form.
IL110943A0 (en) Compositions for the treatment of skin disorders
IL121170A0 (en) Compositions for the treatment of dermatological disorders
HUP9903166A3 (en) Medicinal compositions for the prophylaxis or treatment of arteriosclerosis
FI941826A0 (fi) Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
ZA943744B (en) Therapeutic substituted guanidines
AU2160492A (en) Treatment of human diseases involving dysregulation or dysfunction of the nervous system
GB8900678D0 (en) Compositions for the prevention and medical treatment of parodonthopathy
BG102818A (en) D-manitol and method for its preparation
GB2311940B (en) Pharmaceutical compositions for the treatment of rhinitis
BG102716A (en) Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease.
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
IN167848B (de)
BG102667A (en) Diosgenine-containing composition
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
GR76280B (de)
DE59104412D1 (de) Dynamische Redressionsschiene zur Therapie der Vorfussadduktion.
GB9510162D0 (en) Compositions for the treatment of skin conditions
ZA949564B (en) Method for treating constipation using dimeticone.
HUP9901183A3 (en) Compositions and methods for the prevention and treatment of oral mucositis
AU5546294A (en) Methods and compositions of (-) doxazosin for the treatment of hypertension
ATE72979T1 (de) Zusammenstellung zur behandlung der osteoporose beim menschen.